Level Zero Health banks $6.9M to prove wearable medtech can take the strain out of hormone testing

Level zero healthA female-founded medical device startup that has developed a device to monitor continuous hormone, has aimed to break the new foundation, despite being over a year old, an oversscreen $ 6.9 million pre-beer funds have shut down the round. Startup wants to keep the need to keep away from the requirements of aggressive blood drawings and support research, which can make new treatment for hormone imbalances or even new healthcare innovations, such as separate dosing for hormone-based contraception.

“One of our investors told us that there are some companies that create basic technology and there are some companies that create around the technology; You guys are creating new technology here, “Co-founder and CEO Ulu Rustamova said as we are discussing the latest of the company by the last check in with them End They present on stage when they are disrupted as part of a startup battlefield competition.

“The goal is to create a new market beyond that, right? Similarly CGMS [continuous glucose monitors] Do it They literally, beyond anything, have created a multi -billion dollar market, “He moves forward.” It is defined, a whole new product category of its own – which hopes will inspire people to use devices and data. To create companies and have a riple effect in the next few decades. “

Step -by -step

It may take time to create a whole new product section of any stripe. This is a hardware startup and a medical device to boot, it will not be able to serve an illustration shift on how the clear level zero health is observed overnight hormones.

This is why the team is also working on a stepping stepping stone-use product (illustrated in prototype form), which they are hoping to be cleared for the use of prescriptions next year to support (IVF (IVF) (IVF) (IVF) (IVF ) And low testosterone (TRT).

The current prototype is wearing small needles that allow it to take samples under the skin to detect the trace amount of hormones.

This is one step towards hormone monitoring wearables that they finally expect to bring to market – temporarily ready for 2028 – it is capable of making an continuous measure of issues such as the Inter -last liquid to progesterone, estrogen and testosterone. (It is liquid that fills the spaces around the cells, acts as a mediation between blood plasma and cells – so why biochemical compounds in the blood can be detected in inter -last fluids))

An uninterrupted hormone monitoring device – or rather, the data that it picked up can play a role in enhancing the scientific understanding of the hormones in human biology – a lot of CGM has converted the management of diabetes (And in addition to further)

But Level Zero Health is also creating a business-a B2B business, which is aiming to sell technology on healthcare suppliers-so to summarize the founder time-market and to bridge between the Big Bang Mission, and currently working on the development tracks of development and currently. What is possible

“We think we have this source of truth that we can tap – which is inter -permanent liquid,” Rustamova told Techchen. “And we think there is an instant, short -term product that we should first launch.

“The concept is uninterrupted [hormone monitoring] … Holi Grail – This is the future – because it feels, it is somehow because it is friction again, you can continue it and you can really get a continuous measure. But we also understand that we have to enter the market today where we will not try to change the protocol-and ‘Let’s try this data and explain’ seven years research question-so our first device is actually like a finger stick device. , However this is a patch ””

Prototype is wearing a series of data points with “immediately supply” in the case of use-like IVF, where a woman may need to draw a hormone layer to otherwise monitor The

Rustamova says that the team has finished clinical trials for this single-use interim observation patch and hoping to secure exemptions-the US controller, FDA and a CE marked a CE to allow them to sell their European healthcare to identify ( He says they are not sure which one can come first).

“Hopefully this year we want to show up some level of mutual relations [between levels of hormones the wearable patch can detect and levels detected via a blood draw] -That is what I want to supply with pre-beans, “he added.

CTO and co-founder, Irene Zia, told us that the goal of the team is to show 90%of their patch with the amount of hormone levels in the blood drawings.

Risk vs. Rewards

Although later-when we are discussing the delay in detection through blood-based lessons and inter-permanent fluids, to underscore the risk difference between Rustamova Chims CGM and hormone observation. He noted that the risk for anyone with diabetes (eg, glucose readings in the blood delayed or stopped) is likely to be higher, while hormone observation is not usually higher partner.

“For glucose, you have a possible serious consequence of reading or delay … [but when it comes to hormone monitoring] He told us that the risk of not being like a little deviation or kind of mutual relationship, “He told us.” Obviously we are going to try as much as possible – but here is … this is a very different risk profile. “He further noted that the first in the market CGMs now had less mutual relations with blood reading than these devices.

The suggestion is the goal of the team to extend the bar on accuracy. Which – most likely – because investors were interested in making pile in the early round of this Medtech startup – potential rewards vs. Risks are being positive.

Another – suspicious – here is the helpful cause is that the level of zero health does not fully focus on women’s health problems; Observing male hormones is a key part of the primary business plan. (And it still remains that most technology investors are still betting to solve the problems of talking to their interest.)

The European VC, Radalpine was led by the Pre-Vehicle Fund Round of Level Zero Health. HAX (SOSV), Entrepreneur First (EF), and industrial experts also contributed to this round – SOSV had earlier adopted the startup in its Diptech/hardware Hax Accelerator program and Rustamova was also an EF alum.

Commenting in a statement, Redalpine investor and a level vacant health board member Philip Nays said: “We did it for blood pressure and do it again for the hormone. As one of the sacred grail of diagnostics and the conversion of basic science in engineering, we cannot be more encouraged to convert hormone tracking with their novel biosensors in the uninterrupted hormone measurement of diagnostics. Personalized health management era. “